Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

SAN CARLOS, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of preclinical data from its investigational menin inhibitor icovamenib in combination with semaglutide in a T2D animal model. The oral presentation titled “Icovamenib and Semaglutide Combination Therapy Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model” (Presentation #66), was presented at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting, which takes place September 15 - 19, 2025, in Vienna, Austria.